Biomarin Pharmaceutical
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- -
- Established
- 1997-01-01
- Employees
- -
- Market Cap
- $17.2B
- Website
- http://www.biomarin.com
Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)
Completed
- Conditions
- Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 237
- Registration Number
- NCT00214773
- Locations
- 🇺🇸
Emory University, Decatur, Georgia, United States
🇺🇸Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Fullerton Genetic Center, Asheville, North Carolina, United States
Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels
Phase 3
Completed
- Conditions
- Phenylketonurias
- First Posted Date
- 2005-02-25
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 89
- Registration Number
- NCT00104247
Study of rhASB in Patients With Mucopolysaccharidosis VI
Phase 3
Completed
- Conditions
- Mucopolysaccharidosis VI
- Interventions
- Drug: N-acetylgalactosamine 4-sulfataseDrug: Placebo/rhASB
- First Posted Date
- 2005-02-25
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 39
- Registration Number
- NCT00104234
- Locations
- 🇺🇸
BioMarin Pharmaceutical Inc., Novato, California, United States
Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria
Phase 2
Completed
- Conditions
- Phenylketonurias
- First Posted Date
- 2005-02-25
- Last Posted Date
- 2007-04-09
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 700
- Registration Number
- NCT00104260
Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI
Phase 3
Completed
- Conditions
- Mucopolysaccharidosis VI
- Interventions
- Drug: N-acetylgalactosamine 4-sulfataseDrug: Placebo
- First Posted Date
- 2003-08-25
- Last Posted Date
- 2009-12-24
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 39
- Registration Number
- NCT00067470
- Locations
- 🇺🇸
BioMarin Pharmaceutical Inc., Novato, California, United States
Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI
Phase 2
Completed
- Conditions
- Mucopolysaccharidosis VI
- First Posted Date
- 2002-11-08
- Last Posted Date
- 2009-08-25
- Lead Sponsor
- BioMarin Pharmaceutical
- Registration Number
- NCT00048711
- Locations
- 🇺🇸
BioMarin Pharmaceutical Inc., Novato, California, United States
Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
Phase 1
Completed
- Conditions
- Mucopolysaccharidosis VI
- First Posted Date
- 2002-11-06
- Last Posted Date
- 2006-11-03
- Lead Sponsor
- BioMarin Pharmaceutical
- Registration Number
- NCT00048620
- Locations
- 🇺🇸
BioMarin Pharmaceutical Inc., Novato, California, United States
© Copyright 2025. All Rights Reserved by MedPath